

Supplementary Material

Effectiveness and safety of upadacitinib in treating oligoarticular and polyarticular psoriatic arthritis – primary analysis from the UPJOINT-study

Stephanie Gabriele Werner¹, Ilka Schwarze², Xenofon Baraliakos³, Michael Fiene⁴, Jochen Walter⁵, Tanya Girard⁶, Katharina Jeromin⁷, Marie-Claude Laliberté⁶, Nikola Baschuk⁷, Hugues Allard-Charmand⁸, Louis Bessette⁹, Axel J Hueber^{10, 11}

¹RHIO (Rheumatology, Immunology and Osteology) Duesseldorf and RHIO Research Institute, Duesseldorf, Germany;

²Praxis für Rheumatologie, Leipzig, Germany;

³Rheumazentrum Ruhrgebiet, Ruhr Universität Bochum, Herne, Germany;

⁴Praxis für Rheumatologie, Greifswald, Germany;

⁵Rheumatologische Schwerpunktpraxis, Rendsburg, Germany;

⁶AbbVie Canada, St. Laurent, Quebec, Canada;

⁷AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany;

⁸Division of Rheumatology, Department of Medicine, Université de Sherbrooke, Sherbrooke, Quebec;

⁹Groupe de recherche en rhumatologie et maladies osseuses (GRMO) Québec, Canada;

¹⁰Department of Internal Medicine 3 - Rheumatology and Immunology Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany;

¹¹Division of Rheumatology, Klinikum Nürnberg, Paracelsus Medical University, Nürnberg, Germany.

Correspondence to:

Axel Hueber

Department of Internal Medicine 3 - Rheumatology and Immunology Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Ulmenweg 18, 91054 Erlangen, Germany

Email: axel.hueber@fau.de

Supplementary Table 1. Underlying data for Figures 1a & b

Criterion	Group	Week	N	Total (N)	Percent (%)	95%CI (lower bound)	95%CI (upper bound)
MDA	oPsA	0	10	141	7.1	3.5	12.7
MDA	oPsA	4	48	125	38.4	29.8	47.5
MDA	oPsA	12	65	126	51.6	42.5	60.6
MDA	oPsA	24	67	120	55.8	46.5	64.9
MDA	oPsA	36	54	99	54.5	44.2	64.6
MDA	oPsA	48	47	99	47.5	37.3	57.8
MDA	pPsA	0	3	223	1.3	0.3	3.9
MDA	pPsA	4	33	203	16.3	11.5	22.1
MDA	pPsA	12	67	199	33.7	27.1	40.7
MDA	pPsA	24	58	181	32.0	25.3	39.4
MDA	pPsA	36	54	152	35.5	27.9	43.7
MDA	pPsA	48	54	154	35.1	27.6	43.2
MDA	Total	0	13	364	3.6	1.9	6.0
MDA	Total	4	81	328	24.7	20.1	29.7
MDA	Total	12	132	325	40.6	35.2	46.2
MDA	Total	24	125	301	41.5	35.9	47.3
MDA	Total	36	108	251	43.0	36.8	49.4
MDA	Total	48	101	253	39.9	33.8	46.2
VLDA	oPsA	0	0	141	0.0	0.0	2.6
VLDA	oPsA	4	12	125	9.6	5.1	16.2
VLDA	oPsA	12	20	126	15.9	10.0	23.4
VLDA	oPsA	24	34	120	28.3	20.5	37.3
VLDA	oPsA	36	25	99	25.3	17.1	35.0
VLDA	oPsA	48	22	99	22.2	14.5	31.7
VLDA	pPsA	0	0	223	0.0	0.0	1.6
VLDA	pPsA	4	9	203	4.4	2.0	8.2
VLDA	pPsA	12	23	199	11.6	7.5	16.8
VLDA	pPsA	24	19	181	10.5	6.4	15.9
VLDA	pPsA	36	19	152	12.5	7.7	18.8
VLDA	pPsA	48	22	154	14.3	9.2	20.8
VLDA	Total	0	0	364	0.0	0.0	1.0
VLDA	Total	4	21	328	6.4	4.0	9.6
VLDA	Total	12	43	325	13.2	9.7	17.4
VLDA	Total	24	53	301	17.6	13.5	22.4
VLDA	Total	36	44	251	17.5	13.0	22.8
VLDA	Total	48	44	253	17.4	12.9	22.6

MDA, minimal disease activity; VLDA, very low disease activity; oPsA, oligoarticular psoriatic arthritis; pPsA, polyarticular psoriatic arthritis

Supplementary Table 2. Underlying data for Supplementary Figures 1a & b

Criterion	Group	Week	N	Total (N)	Percent (%)	95%CI (lower bound)	95%CI (upper bound)
MDA	oPsA (pre-treated with ts-/bDMARDs)	0	8	102	7.8	3.4	14.9
MDA	oPsA (pre-treated with ts-/bDMARDs)	4	29	92	31.5	22.2	42.0
MDA	oPsA (pre-treated with ts-/bDMARDs)	12	45	92	48.9	38.3	59.6
MDA	oPsA (pre-treated with ts-/bDMARDs)	24	47	86	54.7	43.5	65.4
MDA	oPsA (pre-treated with ts-/bDMARDs)	36	40	69	58.0	45.5	69.8
MDA	oPsA (pre-treated with ts-/bDMARDs)	48	30	68	44.1	32.1	56.7
MDA	oPsA (ts-/bDMARD-naïve)	0	2	39	5.1	0.6	17.3
MDA	oPsA (ts-/bDMARD-naïve)	4	19	33	57.6	39.2	74.5
MDA	oPsA (ts-/bDMARD-naïve)	12	20	34	58.8	40.7	75.4
MDA	oPsA (ts-/bDMARD-naïve)	24	20	34	58.8	40.7	75.4
MDA	oPsA (ts-/bDMARD-naïve)	36	14	30	46.7	28.3	65.7
MDA	oPsA (ts-/bDMARD-naïve)	48	17	31	54.8	36.0	72.7
MDA	pPsA (pre-treated with ts-/bDMARDs)	0	2	164	1.2	0.1	4.3
MDA	pPsA (pre-treated with ts-/bDMARDs)	4	19	150	12.7	7.8	19.1
MDA	pPsA (pre-treated with ts-/bDMARDs)	12	44	144	30.6	23.2	38.8
MDA	pPsA (pre-treated with ts-/bDMARDs)	24	38	136	27.9	20.6	36.3
MDA	pPsA (pre-treated with ts-/bDMARDs)	36	33	113	29.2	21.0	38.5
MDA	pPsA (pre-treated with ts-/bDMARDs)	48	33	116	28.4	20.5	37.6
MDA	pPsA (ts-/bDMARD-naïve)	0	1	59	1.7	0.0	9.1
MDA	pPsA (ts-/bDMARD-naïve)	4	14	53	26.4	15.3	40.3
MDA	pPsA (ts-/bDMARD-naïve)	12	23	55	41.8	28.7	55.9
MDA	pPsA (ts-/bDMARD-naïve)	24	20	45	44.4	29.6	60.0
MDA	pPsA (ts-/bDMARD-naïve)	36	21	39	53.8	37.2	69.9
MDA	pPsA (ts-/bDMARD-naïve)	48	21	38	55.3	38.3	71.4

Criterion	Group	Week	N	Total (N)	Percent (%)	95%CI (lower bound)	95%CI (upper bound)
MDA	male	0	4	123	3.3	0.9	8.1
MDA	male	4	30	109	27.5	19.4	36.9
MDA	male	12	47	108	43.5	34.0	53.4
MDA	male	24	45	100	45.0	35.0	55.3
MDA	male	36	40	82	48.8	37.6	60.1
MDA	male	48	36	83	43.4	32.5	54.7
MDA	female	0	9	241	3.7	1.7	7.0
MDA	female	4	51	219	23.3	17.9	29.5
MDA	female	12	85	217	39.2	32.6	46.0
MDA	female	24	80	201	39.8	33.0	46.9
MDA	female	36	68	169	40.2	32.8	48.0
MDA	female	48	65	170	38.2	30.9	46.0

MDA, minimal disease activity; oPsA, oligoarticular psoriatic arthritis; pPsA, polyarticular psoriatic arthritis; ts-/bDMARDs, targeted synthetic-/biological disease-modifying antirheumatic drugs

Supplementary Table 3. Underlying data for Figures 2a - g

Criterion	Group	Week	N	Total (N)	Percent (%)	95%CI (lower bound)	95%CI (upper bound)
TJC68 $\leq$ 1	oPsA	0	25	141	17.7	11.8	25.1
TJC68 $\leq$ 1	oPsA	4	70	125	56.0	46.8	64.9
TJC68 $\leq$ 1	oPsA	12	82	126	65.1	56.1	73.4
TJC68 $\leq$ 1	oPsA	24	83	120	69.2	60.1	77.3
TJC68 $\leq$ 1	oPsA	36	68	99	68.7	58.6	77.6
TJC68 $\leq$ 1	oPsA	48	66	99	66.7	56.5	75.8
TJC68 $\leq$ 1	pPsA	0	6	223	2.7	1.0	5.8
TJC68 $\leq$ 1	pPsA	4	48	203	23.6	18.0	30.1
TJC68 $\leq$ 1	pPsA	12	83	199	41.7	34.8	48.9
TJC68 $\leq$ 1	pPsA	24	77	181	42.5	35.2	50.1
TJC68 $\leq$ 1	pPsA	36	78	152	51.3	43.1	59.5
TJC68 $\leq$ 1	pPsA	48	79	154	51.3	43.1	59.4
TJC68 $\leq$ 1	Total	0	31	364	8.5	5.9	11.9
TJC68 $\leq$ 1	Total	4	118	328	36.0	30.8	41.4
TJC68 $\leq$ 1	Total	12	165	325	50.8	45.2	56.3
TJC68 $\leq$ 1	Total	24	160	301	53.2	47.3	58.9
TJC68 $\leq$ 1	Total	36	146	251	58.2	51.8	64.3
TJC68 $\leq$ 1	Total	48	145	253	57.3	51.0	63.5
SJC66 $\leq$ 1	oPsA	0	56	141	39.7	31.6	48.3
SJC66 $\leq$ 1	oPsA	4	92	125	73.6	65.0	81.1
SJC66 $\leq$ 1	oPsA	12	103	126	81.7	73.9	88.1
SJC66 $\leq$ 1	oPsA	24	114	120	95.0	89.4	98.1
SJC66 $\leq$ 1	oPsA	36	96	99	97.0	91.4	99.4
SJC66 $\leq$ 1	oPsA	48	88	99	88.9	81.0	94.3
SJC66 $\leq$ 1	pPsA	0	0	223	0.0	0.0	1.6
SJC66 $\leq$ 1	pPsA	4	70	203	34.5	28.0	41.5
SJC66 $\leq$ 1	pPsA	12	121	199	60.8	53.7	67.6
SJC66 $\leq$ 1	pPsA	24	114	181	63.0	55.5	70.0
SJC66 $\leq$ 1	pPsA	36	108	152	71.1	63.2	78.1
SJC66 $\leq$ 1	pPsA	48	114	154	74.0	66.4	80.8
SJC66 $\leq$ 1	Total	0	56	364	15.4	11.8	19.5
SJC66 $\leq$ 1	Total	4	162	328	49.4	43.9	54.9
SJC66 $\leq$ 1	Total	12	224	325	68.9	63.6	73.9
SJC66 $\leq$ 1	Total	24	228	301	75.7	70.5	80.5
SJC66 $\leq$ 1	Total	36	204	251	81.3	75.9	85.9
SJC66 $\leq$ 1	Total	48	202	253	79.8	74.4	84.6
BSA $\leq$ 3	oPsA	0	117	141	83.0	75.7	88.8
BSA $\leq$ 3	oPsA	4	109	125	87.2	80.0	92.5
BSA $\leq$ 3	oPsA	12	118	126	93.7	87.9	97.2
BSA $\leq$ 3	oPsA	24	111	120	92.5	86.2	96.5
BSA $\leq$ 3	oPsA	36	94	99	94.9	88.6	98.3

Criterion	Group	Week	N	Total (N)	Percent (%)	95%CI (lower bound)	95%CI (upper bound)
BSA $\leq$ 3	oPsA	48	92	99	92.9	86.0	97.1
BSA $\leq$ 3	pPsA	0	177	223	79.4	73.5	84.5
BSA $\leq$ 3	pPsA	4	175	203	86.2	80.7	90.6
BSA $\leq$ 3	pPsA	12	184	199	92.5	87.9	95.7
BSA $\leq$ 3	pPsA	24	165	181	91.2	86.0	94.9
BSA $\leq$ 3	pPsA	36	142	152	93.4	88.2	96.8
BSA $\leq$ 3	pPsA	48	146	154	94.8	90.0	97.7
BSA $\leq$ 3	Total	0	294	364	80.8	76.3	84.7
BSA $\leq$ 3	Total	4	284	328	86.6	82.4	90.1
BSA $\leq$ 3	Total	12	302	325	92.9	89.6	95.5
BSA $\leq$ 3	Total	24	276	301	91.7	88.0	94.6
BSA $\leq$ 3	Total	36	236	251	94.0	90.3	96.6
BSA $\leq$ 3	Total	48	238	253	94.1	90.4	96.6
Pain $\leq$ 1.5	oPsA	0	9	141	6.4	3.0	11.8
Pain $\leq$ 1.5	oPsA	4	33	125	26.4	18.9	35.0
Pain $\leq$ 1.5	oPsA	12	48	126	38.1	29.6	47.2
Pain $\leq$ 1.5	oPsA	24	54	120	45.0	35.9	54.3
Pain $\leq$ 1.5	oPsA	36	44	99	44.4	34.5	54.8
Pain $\leq$ 1.5	oPsA	48	37	99	37.4	27.9	47.7
Pain $\leq$ 1.5	pPsA	0	7	223	3.1	1.3	6.4
Pain $\leq$ 1.5	pPsA	4	34	203	16.7	11.9	22.6
Pain $\leq$ 1.5	pPsA	12	57	199	28.6	22.5	35.5
Pain $\leq$ 1.5	pPsA	24	53	181	29.3	22.8	36.5
Pain $\leq$ 1.5	pPsA	36	43	152	28.3	21.3	36.2
Pain $\leq$ 1.5	pPsA	48	48	154	31.2	24.0	39.1
Pain $\leq$ 1.5	Total	0	16	364	4.4	2.5	7.0
Pain $\leq$ 1.5	Total	4	67	328	20.4	16.2	25.2
Pain $\leq$ 1.5	Total	12	105	325	32.3	27.3	37.7
Pain $\leq$ 1.5	Total	24	107	301	35.5	30.1	41.2
Pain $\leq$ 1.5	Total	36	87	251	34.7	28.8	40.9
Pain $\leq$ 1.5	Total	48	85	253	33.6	27.8	39.8
PtGA $\leq$ 2	oPsA	0	19	141	13.5	8.3	20.2
PtGA $\leq$ 2	oPsA	4	42	125	33.6	25.4	42.6
PtGA $\leq$ 2	oPsA	12	61	126	48.4	39.4	57.5
PtGA $\leq$ 2	oPsA	24	65	120	54.2	44.8	63.3
PtGA $\leq$ 2	oPsA	36	48	99	48.5	38.3	58.7
PtGA $\leq$ 2	oPsA	48	41	99	41.4	31.6	51.8
PtGA $\leq$ 2	pPsA	0	21	223	9.4	5.9	14.0
PtGA $\leq$ 2	pPsA	4	44	203	21.7	16.2	28.0
PtGA $\leq$ 2	pPsA	12	70	199	35.2	28.6	42.2
PtGA $\leq$ 2	pPsA	24	64	181	35.4	28.4	42.8
PtGA $\leq$ 2	pPsA	36	48	152	31.6	24.3	39.6
PtGA $\leq$ 2	pPsA	48	54	154	35.1	27.6	43.2

Criterion	Group	Week	N	Total (N)	Percent (%)	95%CI (lower bound)	95%CI (upper bound)
PtGA $\leq$ 2	Total	0	40	364	11.0	8.0	14.7
PtGA $\leq$ 2	Total	4	86	328	26.2	21.5	31.3
PtGA $\leq$ 2	Total	12	131	325	40.3	34.9	45.9
PtGA $\leq$ 2	Total	24	129	301	42.9	37.2	48.7
PtGA $\leq$ 2	Total	36	96	251	38.2	32.2	44.6
PtGA $\leq$ 2	Total	48	95	253	37.5	31.6	43.8
HAQ-DI $\leq$ 0.5	oPsA	0	38	141	27.0	19.8	35.1
HAQ-DI $\leq$ 0.5	oPsA	4	47	125	37.6	29.1	46.7
HAQ-DI $\leq$ 0.5	oPsA	12	56	126	44.4	35.6	53.6
HAQ-DI $\leq$ 0.5	oPsA	24	62	120	51.7	42.4	60.9
HAQ-DI $\leq$ 0.5	oPsA	36	48	99	48.5	38.3	58.7
HAQ-DI $\leq$ 0.5	oPsA	48	47	99	47.5	37.3	57.8
HAQ-DI $\leq$ 0.5	pPsA	0	37	223	16.6	12.0	22.1
HAQ-DI $\leq$ 0.5	pPsA	4	58	203	28.6	22.5	35.3
HAQ-DI $\leq$ 0.5	pPsA	12	70	199	35.2	28.6	42.2
HAQ-DI $\leq$ 0.5	pPsA	24	57	181	31.5	24.8	38.8
HAQ-DI $\leq$ 0.5	pPsA	36	49	152	32.2	24.9	40.3
HAQ-DI $\leq$ 0.5	pPsA	48	47	154	30.5	23.4	38.4
HAQ-DI $\leq$ 0.5	Total	0	75	364	20.6	16.6	25.1
HAQ-DI $\leq$ 0.5	Total	4	105	328	32.0	27.0	37.4
HAQ-DI $\leq$ 0.5	Total	12	126	325	38.8	33.4	44.3
HAQ-DI $\leq$ 0.5	Total	24	119	301	39.5	34.0	45.3
HAQ-DI $\leq$ 0.5	Total	36	97	251	38.6	32.6	45.0
HAQ-DI $\leq$ 0.5	Total	48	94	253	37.2	31.2	43.4
LEI $\leq$ 1	oPsA	0	113	141	80.1	72.6	86.4
LEI $\leq$ 1	oPsA	4	105	125	84.0	76.4	89.9
LEI $\leq$ 1	oPsA	12	112	126	88.9	82.1	93.8
LEI $\leq$ 1	oPsA	24	109	120	90.8	84.2	95.3
LEI $\leq$ 1	oPsA	36	93	99	93.9	87.3	97.7
LEI $\leq$ 1	oPsA	48	94	99	94.9	88.6	98.3
LEI $\leq$ 1	pPsA	0	144	223	64.6	57.9	70.8
LEI $\leq$ 1	pPsA	4	153	203	75.4	68.8	81.1
LEI $\leq$ 1	pPsA	12	170	199	85.4	79.7	90.0
LEI $\leq$ 1	pPsA	24	156	181	86.2	80.3	90.9
LEI $\leq$ 1	pPsA	36	135	152	88.8	82.7	93.3
LEI $\leq$ 1	pPsA	48	134	154	87.0	80.7	91.9
LEI $\leq$ 1	Total	0	257	364	70.6	65.6	75.2
LEI $\leq$ 1	Total	4	258	328	78.7	73.8	83.0
LEI $\leq$ 1	Total	12	282	325	86.8	82.6	90.3
LEI $\leq$ 1	Total	24	265	301	88.0	83.8	91.5
LEI $\leq$ 1	Total	36	228	251	90.8	86.6	94.1
LEI $\leq$ 1	Total	48	228	253	90.1	85.8	93.5

TJC68/SJC66, tender joint count/swollen joint count including 68/66 joints; BSA, Body Surface Area; PtGA, Patient's Global Assessment of Disease Activity; HAQ-DI, Health Assessment Questionnaire – Disability Index; LEI, Leeds Enthesitis Index; oPsA, oligoarticular psoriatic arthritis; pPsA, polyarticular psoriatic arthritis

Supplementary Table 4. Underlying data for Figures 3a & b

Group	DAPSA Category	Week	N	Total (N)	Percent (%)
oPsA	Remission	0	0	141	0.0
oPsA	LDA	0	29	141	20.6
oPsA	MoDA	0	94	141	66.7
oPsA	HDA	0	15	141	10.6
oPsA	Missing	0	3	141	2.1
oPsA	Remission	4	13	125	10.4
oPsA	LDA	4	66	125	52.8
oPsA	MoDA	4	31	125	24.8
oPsA	HDA	4	4	125	3.2
oPsA	Missing	4	11	123	8.8
oPsA	Remission	12	24	126	19.0
oPsA	LDA	12	68	126	54.0
oPsA	MoDA	12	23	126	18.3
oPsA	HDA	12	5	126	4.0
oPsA	Missing	12	6	126	4.8
oPsA	Remission	24	36	120	30.0
oPsA	LDA	24	50	120	41.7
oPsA	MoDA	24	26	120	21.7
oPsA	HDA	24	3	120	2.5
oPsA	Missing	24	5	120	4.2
oPsA	Remission	36	23	99	23.2
oPsA	LDA	36	52	99	52.5
oPsA	MoDA	36	20	99	20.2
oPsA	HDA	36	1	99	1.0
oPsA	Missing	36	3	99	3.0
oPsA	Remission	48	24	99	24.2
oPsA	LDA	48	41	99	41.4
oPsA	MoDA	48	28	99	28.3
oPsA	HDA	48	1	99	1.0
oPsA	Missing	48	5	99	5.1
pPsA	Remission	0	0	223	0.0
pPsA	LDA	0	1	223	0.4
pPsA	MoDA	0	68	223	30.5
pPsA	HDA	0	147	223	65.9
pPsA	Missing	0	7	223	3.1
pPsA	Remission	4	12	203	5.9
pPsA	LDA	4	47	203	23.2
pPsA	MoDA	4	66	203	32.5
pPsA	HDA	4	39	203	19.2
pPsA	Missing	4	39	203	19.2
pPsA	Remission	12	20	199	10.1
pPsA	LDA	12	88	199	44.2

Group	DAPSA Category	Week	N	Total (N)	Percent (%)
pPsA	MoDA	12	53	199	26.6
pPsA	HDA	12	28	199	14.1
pPsA	Missing	12	10	199	5.0
pPsA	Remission	24	19	181	10.5
pPsA	LDA	24	80	181	44.2
pPsA	MoDA	24	48	181	26.5
pPsA	HDA	24	29	181	16.0
pPsA	Missing	24	5	181	2.8
pPsA	Remission	36	18	152	11.8
pPsA	LDA	36	70	152	46.1
pPsA	MoDA	36	41	152	27.0
pPsA	HDA	36	19	152	12.5
pPsA	Missing	36	4	152	2.6
pPsA	Remission	48	23	154	14.9
pPsA	LDA	48	54	154	35.1
pPsA	MoDA	48	51	154	33.1
pPsA	HDA	48	13	154	8.4
pPsA	Missing	48	13	154	8.4

oPsA, oligoarticular psoriatic arthritis; pPsA, polyarticular psoriatic arthritis; LDA, low disease activity; MoDA, moderate disease activity; HDA, high disease activity


Supplementary Table 5. Underlying data for Figures 4a - c

Criterion	Group	Week	N	Total (N)	Percent (%)	95%CI (lower bound)	95%CI (upper bound)
Stable resolution of dactylitis	oPsA	0	0	17	0.0	0.0	19.5
Stable resolution of dactylitis	oPsA	12	9	17	52.9	27.8	77.0
Stable resolution of dactylitis	oPsA	24	11	17	64.7	38.3	85.8
Stable resolution of dactylitis	oPsA	36	12	17	70.6	44.0	89.7
Stable resolution of dactylitis	oPsA	48	12	17	70.6	44.0	89.7
Stable resolution of dactylitis	pPsA	0	0	42	0.0	0.0	8.4
Stable resolution of dactylitis	pPsA	12	17	42	40.5	25.6	56.7
Stable resolution of dactylitis	pPsA	24	20	42	47.6	32.0	63.6
Stable resolution of dactylitis	pPsA	36	23	42	54.8	38.7	70.2
Stable resolution of dactylitis	pPsA	48	24	42	57.1	41.0	72.3
Stable resolution of dactylitis	Total	0	0	59	0.0	0.0	6.1
Stable resolution of dactylitis	Total	12	26	59	44.1	31.2	57.6
Stable resolution of dactylitis	Total	24	31	59	52.5	39.1	65.7
Stable resolution of dactylitis	Total	36	35	59	59.3	45.7	71.9
Stable resolution of dactylitis	Total	48	36	59	61.0	47.4	73.5
Stable resolution of enthesitis	oPsA	0	0	46	0.0	0.0	7.7
Stable resolution of enthesitis	oPsA	12	26	46	56.5	41.1	71.1
Stable resolution of enthesitis	oPsA	24	30	46	65.2	49.8	78.6
Stable resolution of enthesitis	oPsA	36	30	46	65.2	49.8	78.6
Stable resolution of enthesitis	oPsA	48	31	46	67.4	52.0	80.5
Stable resolution of enthesitis	pPsA	0	0	95	0.0	0.0	3.8
Stable resolution of enthesitis	pPsA	12	38	95	40.0	30.1	50.6
Stable resolution of enthesitis	pPsA	24	40	95	42.1	32.0	52.7
Stable resolution of enthesitis	pPsA	36	40	95	42.1	32.0	52.7

Criterion	Group	Week	N	Total (N)	Percent (%)	95%CI (lower bound)	95%CI (upper bound)
Stable resolution of enthesitis	pPsA	48	43	95	45.3	35.0	55.8
Stable resolution of enthesitis	Total	0	0	141	0.0	0.0	2.6
Stable resolution of enthesitis	Total	12	64	141	45.4	37.0	54.0
Stable resolution of enthesitis	Total	24	70	141	49.6	41.1	58.2
Stable resolution of enthesitis	Total	36	70	141	49.6	41.1	58.2
Stable resolution of enthesitis	Total	48	74	141	52.5	43.9	60.9
Absence of nail psoriasis	oPsA	0	104	141	73.8	65.7	80.8
Absence of nail psoriasis	oPsA	12	100	126	79.4	71.2	86.1
Absence of nail psoriasis	oPsA	24	99	120	82.5	74.5	88.8
Absence of nail psoriasis	oPsA	36	84	99	84.8	76.2	91.3
Absence of nail psoriasis	oPsA	48	88	99	88.9	81.0	94.3
Absence of nail psoriasis	pPsA	0	151	223	67.7	61.1	73.8
Absence of nail psoriasis	pPsA	12	167	199	83.9	78.1	88.7
Absence of nail psoriasis	pPsA	24	159	181	87.8	82.2	92.2
Absence of nail psoriasis	pPsA	36	137	152	90.1	84.2	94.4
Absence of nail psoriasis	pPsA	48	140	154	90.9	85.2	94.9
Absence of nail psoriasis	Total	0	255	364	70.1	65.1	74.7
Absence of nail psoriasis	Total	12	267	325	82.2	77.5	86.2
Absence of nail psoriasis	Total	24	258	301	85.7	81.2	89.5
Absence of nail psoriasis	Total	36	221	251	88.0	83.4	91.8
Absence of nail psoriasis	Total	48	228	253	90.1	85.8	93.5

oPsA, oligoarticular psoriatic arthritis; pPsA, polyarticular psoriatic arthritis


Supplementary Figure 1a. Achievement of minimal disease activity (MDA) stratified by PsA phenotype in combination with ts-/bDMARD treatment status



Error bars represent 95% confidence intervals (CIs). Further data, including absolute numbers and 95% CIs, are provided in Supplementary Table 2.

MDA, minimal disease activity; oPsA, oligoarticular psoriatic arthritis; pPsA, polyarticular psoriatic arthritis; ts-/bDMARDs, targeted synthetic-/biological disease-modifying antirheumatic drugs

Supplementary Figure 1b. Achievement of minimal disease activity (MDA) stratified by gender



Error bars represent 95% confidence intervals (CIs). Further data, including absolute numbers and 95% CIs, are provided in Supplementary Table 2.

MDA, minimal disease activity